Mobile

A Phase II, Observer-Blind, Randomized, Parallel Groups, Single Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of FLUAD™ versus...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-003181-34

A Phase II, Observer-Blind, Randomized, Parallel Groups, Single Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of FLUAD™ versus Two 0.25mL Intramuscular Doses of Vaxigrip™ Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the immunogenicity of one 0.25 mL intramuscular (IM) injection of FLUAD influenza vaccine and that of two 0.25 mL IM injections of the conventional influenza vaccine Vaxigrip, in terms of post-immunization geometric mean titers (GMTs), as measured by HI test.

Critère d'inclusion

  • Influenza (vaccine trial)

Liens